- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:07 | Abpro Corporation: Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers | 33 | GlobeNewswire (Europe) | IND submitted for ABP-102/CT-P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable safety profile ABP-102/CT-P72 represents... ► Artikel lesen | |
| ABPRO Aktie jetzt für 0€ handeln | |||||
| Di | Abpro secures Nasdaq extension to regain compliance with listing rules | 1 | Seeking Alpha | ||
| Di | Abpro Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.11. | Abpro Holdings, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 14.11. | Abpro Holdings, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11. | Abpro Holdings, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 04.11. | Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager | 2 | GlobeNewswire (USA) | ||
| 03.11. | Abpro completes 1-for-30 reverse stock split to maintain Nasdaq listing | 1 | Investing.com | ||
| 03.11. | Abpro Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.10. | Abpro Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.10. | Abpro Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.10. | Abpro Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.08. | Abpro Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 24.07. | Abpro Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.06. | Abpro Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 27.04. | Abpro Corporation: Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager | 259 | GlobeNewswire (Europe) | Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profileAbpro and Celltrion have a strategic partnership for worldwide development and commercialization... ► Artikel lesen | |
| 10.03. | Abpro Corporation: Abpro Statement on the Departure of Former CEO Ian Chan | 387 | GlobeNewswire (Europe) | WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening... ► Artikel lesen | |
| 19.12.24 | Pre-market Movers: PainReform, CURRENC Group, Bio-Path Holdings, Abpro Corporation, KULR Technology | 1.119 | AFX News | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green PainReform Ltd. (PRFX) is up over... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,335 | -0,70 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| IMMUNOME | 23,920 | +21,92 % | Immunome's desmoid tumor treatment triumphs in phase 3, setting up approval filing | ||
| KYVERNA THERAPEUTICS | 11,265 | +28,30 % | Kyverna Therapeutics, Inc.: Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome | Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 Miv-cel... ► Artikel lesen | |
| RADIOPHARM THERANOSTICS | 11,750 | +190,12 % | Radiopharm Theranostics: 92 % der Probanden erreichen primären Endpunkt in RAD101-Studie | ||
| PRAXIS PRECISION MEDICINES | 276,01 | +2,62 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| BIONTECH | 80,00 | -0,99 % | BioNTech SE: Erste Ergebnisse aus BioNTechs und BMS' globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig zeigten ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem dreifach negativem Brustkrebs | Zwischenergebnisse der globalen klinischen Phase-2-Studie bei lokal fortgeschrittenem/metastasiertem dreifach negativem Brustkrebs (triple-negative breast cancer, "TNBC") zeigten eine ermutigende Anti-Tumor-Aktivität... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 85,34 | -4,83 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 38,950 | -3,85 % | Harmony Biosciences Holdings, Inc.: Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress | Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,78 | -0,07 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| CLIMB BIO | 4,020 | +34,00 % | Climb Bio, Inc. - 8-K, Current Report | ||
| OLEMA PHARMACEUTICALS | 35,680 | +7,99 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| IMMUNOVANT | 25,810 | -2,35 % | Immunovant: 550-Millionen-Dollar-Kapitalerhöhung und neue Studiendetails | ||
| VERA THERAPEUTICS | 50,20 | +0,84 % | Vera Therapeutics, Inc. - 8-K, Current Report | ||
| ARTIVA BIOTHERAPEUTICS | 5,220 | +59,15 % | Artiva Biotherapeutics, Inc. - 8-K, Current Report | ||
| EVOTEC | 5,190 | -0,95 % | Evotec: Es ist vollbracht! | Der Hamburger Wirkstoffforscher Evotec hat am Montagmorgen den abgeschlossenen Verkauf seines Standortes in Toulouse an Sandoz bekanntgegeben. Evotec: Toulouse-Verkauf an Sandoz abgeschlossen Für Evotec... ► Artikel lesen |
Das Unternehmen ABPRO HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,85 % bei einem Aktienkurs von 5,820 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABPRO HOLDINGS INC finden Sie auf Wallstreet Online.